-
Prognostic Value of ABPMs in patients with Treated Hypertension; Tazarotene Cream in the Treatment of Psoriasis; Antihyperglycemic Effect of Oolong Tea in Type 2 Diabetes; Metformin and Thiazolidinedione Use in Medicare Patients with Heart Failure; Alcohol Consumption Patterns and Biologic Markers of Glycemic Control; Azelaic Acid Gel as a New Treatment for Papulopustular Rosacea
-
-
Based on a patients lipoprotein abnormality, the algorithm described in this review begins with achievable, practical therapeutic lifestyle changes and then adds pharmacologic agents in stepwise fashion to address abnormalities of LDL cholesterol, triglycerides, and HDL cholesterol. While the approach is aggressive, it is not based on driving lipid levels to extremely low levels. While some of the lipid targets appear less stringent than conventional wisdom would suggest (eg, accepting an LDL cholesterol target of 130 mg/dL), the approach is in compliance with the spirit and letter of national guidelines.
-
Of 26 mechanically ventilated patients, 22 developed bacterial lower respiratory tract colonization, and in 15 patients anaerobes were recovered; 2 of 5 patients diagnosed with ventilator-associated pneumonia had anaerobes present in sufficient quantity to suggest that they were considered pathogenic.
-
-
-
The FDA has approved vardenafil (LevitraBayer and GlaxoSmithKline) for the treatment of erectile dysfunction in men. Vardenafil joins sildenafil (Viagra) as the only 2 drugs approved for this indication in this country.
-
Specialty beds marketed for ICU patients range from simple air-filled mattresses designed for use on ordinary hospital beds to high-tech, electronically controlled rotating or vibrating devices.
-
The ARDSNetwork trial that began in 1996 (ARMA trial)1 was designed to test the validity of using lower tidal volumes in mechanical ventilators was halted because critics who were not a part of the ARDSNetwork argued that the control arm chosen was harmful and unethical.
-
A wide variety of therapeutic interventions have failed to produce a significant change in the mortality of critically ill patients. Studies of these interventions include numerous trials of anti-inflammatory agents in sepsis, the trial involving growth hormone in critically ill patients, as well as a host of other investigations.